AGITG 2013* Andrew Barbour
University of Queensland, QLD, Australia
- This delegate is presenting an abstract at this event.
Presentations this author is a contributor to:
A Randomised Phase II Trial of Pre-operative cisplatin, 5 fluorouracil anddocetaxel ± Radiotherapy based on poor early response to standardchemotherapy for resectable adenocarcinoma of the oesophagus and/or OGJunction (10521)
10:30 AM
Andrew Barbour
Advanced Oesophageal Cancer (AGITG/ANZGOSA combined session)
Phase II study of pre-operative Gemcitabine and nab-Paclitaxel forResectable Pancreas Cancer. (10526)
5:00 PM
Andrew Barbour
Pancreatic Cancer
Molecular Fingerprints: Where are we now? (10557)
10:30 AM
Andrew Barbour
Advanced Oesophageal Cancer (AGITG/ANZGOSA combined session)